{
     "PMID": "14556797",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20040420",
     "LR": "20141120",
     "IS": "0968-0896 (Print) 0968-0896 (Linking)",
     "VI": "11",
     "IP": "22",
     "DP": "2003 Nov 3",
     "TI": "Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands.",
     "PG": "4807-13",
     "AB": "The present study describes the synthesis and pharmacological profile of three novel heterocyclic compounds originally designed, on the basis of bioisosterism, as dopamine D2 receptor ligands: 1-[1-(4-chlorophenyl)-1H-pyrazol-4-ylmethyl]-4-phenyl-piperazine (LASSBio-579), 1-phenyl-4-(1-phenyl-1H-[1,2,3]triazol-4-ylmethyl)-piperazine (LASSBio-580) and 1-[1-(4-chlorophenyl)-1H-[1,2,3]triazol-4-ylmethyl]-4-phenyl-piperazine (LASSBio-581). Binding studies performed on brain homogenate indicated that all three compounds bind selectively to D2 receptors. In addition, electrophysiological studies carried out in cultured hippocampal neurons suggested that LASSBio-579 and 581 act as D2 agonists, whereas LASSBio-580 acts as a D2 antagonist.",
     "FAU": [
          "Menegatti, Ricardo",
          "Cunha, Anna C",
          "Ferreira, Vitor F",
          "Perreira, Edna F R",
          "El-Nabawi, Ahmed",
          "Eldefrawi, Amira T",
          "Albuquerque, Edson X",
          "Neves, Gilda",
          "Rates, Stela M K",
          "Fraga, Carlos A M",
          "Barreiro, Eliezer J"
     ],
     "AU": [
          "Menegatti R",
          "Cunha AC",
          "Ferreira VF",
          "Perreira EF",
          "El-Nabawi A",
          "Eldefrawi AT",
          "Albuquerque EX",
          "Neves G",
          "Rates SM",
          "Fraga CA",
          "Barreiro EJ"
     ],
     "AD": "Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, PO Box 68006, RJ 21944-970 Rio de Janeiro, Brazil.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "Bioorg Med Chem",
     "JT": "Bioorganic & medicinal chemistry",
     "JID": "9413298",
     "RN": [
          "0 (Dopamine D2 Receptor Antagonists)",
          "0 (Ligands)",
          "0 (Piperazines)",
          "0 (Receptors, Dopamine D1)",
          "0 (Receptors, Dopamine D2)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Brain/metabolism",
          "Cell Membrane/metabolism",
          "*Dopamine D2 Receptor Antagonists",
          "Dose-Response Relationship, Drug",
          "Drug Design",
          "Electrophysiology",
          "Hippocampus/cytology",
          "Ligands",
          "Male",
          "Models, Molecular",
          "Neurons/drug effects/physiology",
          "Piperazines/*chemical synthesis/chemistry/metabolism/*pharmacology",
          "Radioligand Assay",
          "Rats",
          "Receptors, Dopamine D1/metabolism",
          "Receptors, Dopamine D2/*agonists/metabolism"
     ],
     "EDAT": "2003/10/15 05:00",
     "MHDA": "2004/04/21 05:00",
     "CRDT": [
          "2003/10/15 05:00"
     ],
     "PHST": [
          "2003/10/15 05:00 [pubmed]",
          "2004/04/21 05:00 [medline]",
          "2003/10/15 05:00 [entrez]"
     ],
     "AID": [
          "S0968089603004875 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Bioorg Med Chem. 2003 Nov 3;11(22):4807-13.",
     "term": "hippocampus"
}